Tyligand Bioscience Ltd. HKEX Listing Application Lapses; Core Candidate Enters Phase 2 Clinical Trials
NewTimeSpace News: The listing application submitted by Tyligand Bioscience Ltd. to the Hong Kong Stock Exchange on 29 January 2026 has lapsed upon expiry of the six-month term. CICC served as the original sole sponsor.
Founded in 2017, the Company is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative anti-tumour therapies. As of the latest practicable date, its pipeline comprises four drug candidates: TSN1611, the core candidate in Phase 2 clinical trials; an additional clinical-stage candidate TSN222; and two preclinical candidates TSNA1789 and TSNA3339.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- ETF Financing Ranking | J.P.Morgan Asset Management S&P Access Hong Kong Low Volatility High Dividend ETF (513630) had a net financing buy-in of CNY 10.68 million on Aug 4, ranked top among comparable funds
- Csop Hang Seng China Enterprises Index Daily (2x) Leveraged Product (07288.HK) Rises 0.86% Intraday, NAV Per Unit at HK$3.037
- ETF Financing Ranking | Bosera S&P 500 ETF (513500) had a net financing buy-in of CNY 21.51 million on Aug 4, ranked in the first tier of the entire market
- ETF Financing Ranking | Guotai CSI Semiconductor Material Equipment Theme ETF (159516) had a net financing buy-in of CNY 103.26 million on Aug 4, ranked first in the entire market
